Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Super CAR-T in Advanced Hepatocellular Carcinoma
NCT07493044Phase 1Recruiting
- Sponsor
- Guangzhou FineImmune Biotechnology
- Start
- Mar 2026
- Primary completion
- Apr 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Super CAR-T in hepatocellular carcinoma (HCC), sponsored by Guangzhou FineImmune Biotechnology. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Started Mar 2026; status: recruiting.
02
Drugs
Super CAR-T
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07493044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493044.